Hydrogen peroxide and nitric oxide in exhaled air of children with cystic fibrosis during antibiotic treatment.
Cystic fibrosis (CF) patients characteristically have severe chronic airway inflammation associated with bacterial infection. A noninvasive marker of airway inflammation could be a useful guide to treatment of CF lung disease. The aim of this study was to assess whether measurement of hydrogen peroxide (H2O2) and nitric oxide (NO) in exhaled air can serve to monitor the effect of treatment with antibiotics in CF-children with acute infective pulmonary exacerbations. Sixteen CF-patients (mean age 12.3 yrs) with exacerbation of their lung infection were treated with intravenous antibiotics in an uncontrolled study. During treatment, H2O2 in exhaled air condensate was measured twice a week. In addition, serial NO measurements were performed in nine patients. During antibiotic treatment the median H2O2 concentration in exhaled air condensate decreased significantly from 0.28 microM (range 0.07-1.20 microM) to 0.16 microM (range 0.05-0.24 microM, p=0.002) and the mean forced expiratory volume in one second significantly increased from 55% predicted to 75% pred (p=0.001). In individual subjects, changes of H2O2 and FEV1 between pairs of serial measurements correlated weakly (p=0.08). Data on exhaled NO were inconclusive; exhaled NO did not change systematically during treatment. It is concluded that cystic fibrosis patients with an acute pulmonary exacerbation have abnormally high concentrations of hydrogen peroxide, but not of nitric oxide, in exhaled air, which decrease during intravenous antibiotic treatment. Further controlled studies should establish if exhaled hydrogen peroxide, may serve as a noninvasive parameter of airway inflammation to guide antibiotic treatment in cystic fibrosis lung disease.
Jöbsis
Q
Q
Dept of Paediatrics/Respiratory Medicine, University Hospital, Maastricht, The Netherlands.
Raatgeep
H C
HC
Schellekens
S L
SL
Kroesbergen
A
A
Hop
W C
WC
de Jongste
J C
JC
D000208:Acute Disease; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001944:Breath Tests; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications / Q000378:metabolism / Q000473:pathology*; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D006861:Hydrogen Peroxide / Q000032:analysis*; D008297:Male; D009569:Nitric Oxide / Q000032:analysis*; D012141:Respiratory Tract Infections / Q000150:complications / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D009569:Nitric Oxide; D006861:Hydrogen Peroxide